Jazz Pharmaceuticals plc Net Income Loss

• Jazz Pharmaceuticals plc showed a decrease of -163.6% in Net Income Loss from 2024 to 2025.
• This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Jazz Pharmaceuticals plc's Net Income Loss has declined by 5,109.9%.
• Historical annual values: Fiscal year 2025: -$356.15 million | Fiscal year 2024: $560.12 million | Fiscal year 2023: $414.83 million | Fiscal year 2022: -$224.06 million | Fiscal year 2021: -$329.67 million | Fiscal year 2020: $238.62 million | Fiscal year 2019: $523.37 million | Fiscal year 2018: $447.10 million | Fiscal year 2017: $487.85 million | Fiscal year 2016: $396.83 million | Fiscal year 2015: $329.54 million | Fiscal year 2014: $58.39 million | Fiscal year 2013: $216.31 million | Fiscal year 2012: $288.59 million | Fiscal year 2011: $124.98 million | Fiscal year 2010: $32.78 million | Fiscal year 2009: -$6.84 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026